[{"orgOrder":0,"company":"Arctic Therapeutics","sponsor":"EIC Fund","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"ICELAND","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"Grapiprant","moa":"Aldose reductase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Arctic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Arctic Therapeutics \/ EIC Fund","highestDevelopmentStatusID":"8","companyTruncated":"Arctic Therapeutics \/ EIC Fund"}]

Find Clinical Drug Pipeline Developments & Deals by Arctic Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : The financing aims to fund the development of AT-001 an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain. It is being evaluated for treating HCCAA.

                          Product Name : AT-001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 22, 2025

                          Lead Product(s) : Grapiprant

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : EIC Fund

                          Deal Size : $27.7 million

                          Deal Type : Series A Financing

                          blank